Alnylam Pharmaceuticalsvs.Incyte
ALNY vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.3× larger than Incyte by market cap; Incyte trades at the lower P/E (14.2 vs 37.2); year to date, Incyte leads (+14.2% vs −43.5%).
Side by side
| ALNY | INCY | |
|---|---|---|
| Market cap | $30B | $22.9B |
| Price | $232.68 | $112.79 |
| Today | +3.6% | +0.0% |
| Return YTD | −43.5% | +14.2% |
| Return 1Y | −50.2% | +32.1% |
| Since June 26, 2026 | −20.1% | −0.8% |
| P/E | 37.2 | 14.2 |
| P/S | 6.3 | 3.9 |
| P/B | 22.2 | 3.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More ALNY & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.